PARP1 and ovarian carcinoma: In this review, we discuss in detail the molecular mechanisms by which PARP inhibitor treatment induces immune responses, summarize available clinical data on combination therapy in ovarian cancer, and explore the potential predictive biomarkers that are utilized to guide the use of combination therapy